Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs PTCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTCT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

PTCT Overall Winner 6-Pillar Tally: IONS 2 – 4 PTCT Matrix Metrics: IONS 2 – 8 PTCT

As of Nov 16, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas PTCT carries 45.4/100 (HOLD) at $61.62 (19.9x Forward P/E, 21.5% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTCT 45.4/100 HOLD), PTCT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. -58.8% operating margin) and revenue trajectory (+69.6% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile PTCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs PTCT
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
PTCT NASDAQ Head-to-Head Winner
PTC Therapeutics, Inc.
Pharmaceutical Preparations
$61.62
-2.95% 1D
Market Cap $5.3B
TTM Revenue $1.16B
Forward P/E 19.9x
Beta / 30D Vol 0.81β · 58% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 48.0 Fund 54.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $63.57 · SMA50: $63.96

6-Pillar Scorecard Institutional Category Breakdown (IONS 2 – 4 PTCT)

Columns: Metric · IONS · PTCT
1. Valuation Multiples PTCT
Forward P/E 90.9x 19.9x
Trailing P/E 90.9x 19.4x
PEG Ratio N/M 0.81x
EV / Revenue 6.2x 4.7x
2. Growth & Scale PTCT
Revenue Growth (YoY) +54.9% +69.6%
Earnings Growth (YoY) -43.7% +0.0%
TTM Revenue (USD) $960M $1.16B
Market Cap $4.7B $5.3B
3. Profitability & Quality PTCT
Gross Margin 3.0% 55.2%
Operating Margin -58.8% 21.5%
Net Profit Margin -56.9% -9.2%
Return on Equity (ROE) -108.0% -7740.1%
4. Balance Sheet & Cash Flow PTCT
Cash Generation (TTM) -$623M -$41M
Cash Flow Margin -64.9% -3.6%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $127M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IONS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 59.9% (17th %ile) 55.7% (17th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.18x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) 33.7% of Rev ($389M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (2) vs PTCT (8)
Institutional Metric IONS PTCT Criterion Row Edge
Market Capitalization
Scale
$4.7B $5.3B Larger Scale PTCT
Trailing P/E Ratio
Valuation
90.9x 19.4x Lower Multiple PTCT
Forward P/E Ratio
Valuation
90.9x 19.9x Lower Multiple PTCT
Revenue Growth (YoY)
Growth
+54.9% +69.6% Higher Growth PTCT
Operating Margin (TTM)
Profitability
-58.8% 21.5% Higher Margin PTCT
Net Profit Margin
Profitability
-56.9% -9.2% Higher Margin PTCT
Return on Equity (ROE)
Capital Efficiency
-108.0% -7740.1% Higher ROE IONS
52-Week Range Position
Momentum
2% ($27–$87) 9% ($59–$91) Stronger Trend PTCT
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 0.81β · 58% Vol Lower Realized Risk PTCT
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 45.4 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $1.16B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 55.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev 0.81x PEG · 4.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) -$41M ($127M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTCT +37.5 pp
IONS: -33.48% · PTCT: +4.02%
3M Horizon PTCT +36.93 pp
IONS: -52.09% · PTCT: -15.16%
6M Horizon PTCT +48.45 pp
IONS: -60.61% · PTCT: -12.16%
1Y Horizon PTCT +41.31 pp
IONS: -59.1% · PTCT: -17.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue PTCT Revenue IONS Op. Margin PTCT Op. Margin Margin Leader
FY2018 $600M $260M -10.2% -43.7% IONS
FY2019 $1.12B $310M 32.6% -78.6% IONS
FY2020 $730M $380M -23.6% -113.4% IONS
FY2021 $810M $540M -3.7% -69.5% IONS
FY2022 $590M $700M -69.8% -64.0% PTCT
FY2023 $790M $940M -44.9% -46.9% IONS
FY2024 $710M $810M -67.4% -37.5% PTCT
FY2025 $940M $1.73B -40.4% 50.1% PTCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTCT BREAKDOWN
91d in phase · OBV DISTRIBUTION
Current IV 55.7%
IV Percentile 17th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PTCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
PTCT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 21.5% operating margin.
OpEx & R&D Reinvestment 33.7% of Rev ($389M)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs PTCT Key Questions & Quantitative Answers

As of Nov 16, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas PTCT carries 45.4/100 (HOLD) at $61.62 (19.9x Forward P/E, 21.5% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTCT 45.4/100 HOLD), PTCT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. -58.8% operating margin) and revenue trajectory (+69.6% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile PTCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTCT leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with PTCT at +69.6% YoY revenue growth and +0.0% YoY earnings growth on $1.16B TTM revenue (55.2% gross margin, 21.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while PTCT shifted +565.4%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($389M) (0 disclosures) for PTCT.

PTCT screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas PTCT trades at 19.9x Forward P/E, 19.4x Trailing P/E, 0.81x PEG, and 4.7x EV/Revenue (-3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus PTCT (-7740.1% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, PTCT carries 55.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.81β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.